WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Fougera Pharmaceuticals Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Pharmacy Market
Eirion Therapeutics, Inc. | September 09, 2021
Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion's exclusive botulinum active pharmaceutical ingredient (API) manufacturer. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and prima...
DECK 7 | February 04, 2020
Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...
Drugs | April 19, 2020
Despite increased demand for inhalers in some parts of the United States, Americans with asthma shouldn't ration their medications during the coronavirus pandemic, the American Lung Association says. Rescue inhalers are in short supply in some areas because hospitals are giving albuterol to COVID-19 patients with severe symptoms to help them breathe, the group explained. Albuterol is a quick-relief medication used to treat shortness of breath and wheezing in people with asthma and some other...
Business Insights, PHARMACY MARKET
Harrow | February 16, 2023
On February 15, 2023, Harrow, a renowned pharmaceutical firm specializing in eyecare in the United States, announced the launch of its next-generation, patent-pending compounded Atropine formulations. These formulations are now accessible through ImprimisRx, a mail-order pharmacy subsidiary wholly owned by Harrow. The following are the key features of ImprimisRx's next-generation Atropine formulations Thoroughly validated analytical tests are conducted to...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE